Phase IIb Open-label Trial of SUBA-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

Trial Profile

Phase IIb Open-label Trial of SUBA-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Itraconazole (Primary)
  • Indications Basal cell nevus syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms SCORING
  • Sponsors HedgePath Pharmaceuticals
  • Most Recent Events

    • 30 Oct 2017 According to a HedgePath Pharmaceuticals media release, the company intends to lock database to complete a Clinical Study Report during the first quarter of 2018 while at the same time preparing for submission of a pre-NDA meeting request to the FDA.
    • 15 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 08 Aug 2017 Planned End Date changed from 1 Nov 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top